CareDx Announces Study Showing AlloSeq cfDNA Highly Accurate in Detecting Rejection in Organ Transplant Patients
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced findings published in Transplant International 1 that show the performance of AlloSeq™ cfDNA in detecting allograft rejection was consistent with its AlloSure® lab developed test.
Kidney allograft rejection is the leading cause of graft failure in kidney transplant patients. Early identification and treatment of rejection is critical to reduce allograft injury and prevent irreversible damage to the transplanted organ. Traditional tests such as serum creatinine, proteinuria and the formation of donor specific antibodies (DSA) are lagging indicators of kidney allograft rejection. In this first large-scale comparative study of its kind, AlloSure and AlloSeq cfDNA demonstrate consistent performance in detecting both clinical and subclinical rejection.
'This large-scale multicenter study confirms that the AlloSeq cfDNA IVD kit performance in detecting allograft rejection is highly consistent with the broadly implemented and well-characterized AlloSure Kidney testing service,' said Dr. Alexandre Loupy, Professor of Nephrology and Epidemiology at the Necker Hospital, in Paris, and Director of Inserm French NIH unit and head of the Paris Institute for Transplantation and Organ Regeneration (PITOR). 'We believe that this study will be a key driver in increasing adoption of cell-free DNA in monitoring patients for early signs of rejection.'
The multicenter prospective study included 580 kidney transplant patients from three referral transplant centers in Europe. The study showed that AlloSeq cfDNA was highly accurate in detecting allograft rejection in kidney transplant patients, with a significant difference between rejection and non-rejection ( p <0.0001) and an AUC of 0.758. Consistency in performance between AlloSeq cfDNA and AlloSure Kidney dd-cfDNA was confirmed across clinical scenarios including post-transplant timepoints, allograft stability, and allograft rejection subcategories; each compared to biopsy proven rejection.
'This study demonstrates the strong performance of our AlloSeq cfDNA kit in assessing allograft rejection in kidney transplant patients,' said John W. Hanna, CareDx President and CEO. 'We look forward to physicians' use of this data to expand the use of our innovative, high-performance allograft monitoring solutions internationally. Approximately 18,000 kidney transplants are performed in the European Union annually. By identifying early signs of rejection with AlloSeq cfDNA, physicians can intervene earlier to prevent irreversible organ injury and failure and improve long-term outcomes for their patients.'
To read the publication, go here.
AlloSeq cfDNA is available with CE-IVD marking in the E.U. and in the U.K. Not available in the U.S.
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit www.caredx.com.
Forward Looking Statements
This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with AlloSeq cfDNA and AlloSure dd-cfDNA. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, all of which are difficult to predict and many of which are beyond CareDx's control, that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of AlloSeq cfDNA or AlloSure or risks that the findings published in the Transplant International study supporting the data may be inaccurate. These statements are also subject to general economic and market factors; and other risks discussed in CareDx's filings with the Securities and Exchange Commission (the 'SEC'), including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed by CareDx with the SEC on February 28, 2024, the Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 filed by CareDx with the SEC on May 9, 2024 and the Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 filed by CareDx with the SEC on July 31, 2024, the Quarterly Report on Form10-Q for the quarter ended September 30, 2024 filed by CareDx with the SEC on November 4, 2024, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx's actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx's forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
Loupy, A, Certain, A, Tangprasertchai, NS, et al. Evaluation of a Decentralized Donor-Derived Cell-Free DNA Assay for Kidney Allograft Rejection Monitoring. Transplant International (2024). DOI=10.3389/ti.2024.13919
Media Contacts
Anna Czene
818-731-2203
[email protected] Relations
INDUSTRY KEYWORD: BIOTECHNOLOGY SURGERY HEALTH GENETICS CLINICAL TRIALS
SOURCE: CareDx, Inc.
Copyright Business Wire 2025.
PUB: 02/20/2025 07:05 AM/DISC: 02/20/2025 07:07 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
S&P 500 Gains & Losses Today: J.M. Smucker Stock Sinks, Tesla Shares Recover
The S&P 500 added 0.6% on Tuesday, June 10, 2025, as investors awaited developments in trade negotiations between the U.S. and China. Tesla shares moved higher as social media posts from CEO Elon Musk promoted the company's upcoming robotaxi launch. Declining sales of sweet baked goods weighed on the performance J.M. Smucker, and shares of the food maker U.S. equities indexes climbed Tuesday as trade representatives from the U.S. and China engaged in talks for a second straight day. Both the S&P 500 and the Nasdaq ended the session with gains of around 0.6%, while the Dow was up 0.3%. Read Investopedia's full coverage of the day's trading here. Intel (INTC) shares surged nearly 8%, gaining the most of any stock in the S&P 500. Shares of other semiconductor makers also moved higher as the U.S.-China talks bolstered hopes for looser export restrictions. Although Apple (AAPL) said it will end support next year for Mac computers built with Intel's processors, providing more evidence of the transitional period faced by the chipmaker, analysts have expressed confidence in the ability of CEO Lip-Bu Tan, who took the reins of in March, to drive a turnaround at Intel. Caesars Entertainment (CZR) shares jumped 5.7%. TD Cowen analysts reiterated a "buy" rating on the casino operator's stock, noting that the company's loyalty program has helped drive entertainment, food and beverage, and lodging revenues to supplement its traditional earnings from gaming operations. The analysts also pointed to potential growth in its digital business. Tesla (TSLA) stock also added 5.7% as social-media posts from CEO Elon Musk hinted at the impending launch of the company's autonomous ride hailing service in Austin, Texas. Tuesday's move higher extended a recovery for the stock that kicked into gear during the previous session as tensions appeared to ease between Musk and President Donald Trump. Warner Bros. Discovery (WBD) shares advanced 5%, a day after the media conglomerate announced plans to split into two companies. One entity will house Warner's TV and movie studios along with the HBO Max streaming service, while the other will be home to its cable channels and the Discovery+ streaming service. The stock initially surged following the Monday-morning announcement, gave back those gains to end Monday's session lower, and then rose again today. Food maker J.M. Smucker (SJM) reported lower-than-expected sales for its fiscal fourth quarter of 2025, and its profit guidance for fiscal 2026 also came in below expectations. The maker of Folgers coffee and Uncrustables handheld sandwiches said that volume/mix impacts contributed to a year-over-year decline in net sales, especially declines in dog treats and sweet baked goods. Smucker shares sank nearly 16%, losing the most of any S&P 500 stock on Tuesday. Universal Health Services (UHS) fell 2.9% on Tuesday, extending losses posted in the prior session after the hospital operator's chief financial officer discussed a decline in the volume of surgical procedures at its facilities. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Los Angeles Times
an hour ago
- Los Angeles Times
US stocks drift closer to their record as Wall Street waits to see what US-China talks will bear
NEW YORK — U.S. stocks drifted closer to their all-time high on Tuesday as the wait continued to hear what will come of trade talks between the United States and China. The S&P 500 rose 0.5% as talks between the world's two largest economies carried into a second day. The Dow Jones Industrial Average added 105 points, or 0.2%, and the Nasdaq composite gained 0.6%. Stocks have roared higher since dropping roughly 20% below their record two months ago, when President Donald Trump shocked financial markets with his announcement of tariffs that were so stiff that they raised worries about a possible recession. Much of the rally has been due to hopes that Trump would lower his tariffs after reaching trade deals with countries around the world, and the S&P 500 is back within 1.7% of its record set in February. It's getting to be time to see whether such hopes were warranted. The talks with China were going 'really, really well,' U.S. Secretary of Commerce Howard Lutnick said Tuesday evening in London, where the talks were being held. The two sides worked on 'all sorts of trade issues,' he said, according to a video clip posted by the Chinese state broadcaster CGTN. Both the United States and China have put many of their tariffs announced against each other on pause as talks continue. Even though many tariffs are on hold for the moment, they're still affecting companies and their ability to make profits because of all the uncertainty they've created. Designer Brands, the company behind the DSW shoe store chain, became the latest U.S. company to yank its financial forecasts for 2025 because of 'uncertainty stemming primarily from global trade policies.' The company, which also owns the Keds, Jessica Simpson and other shoe brands, reported a larger loss for the start of the year than analysts were expecting, and its revenue also fell short of forecasts. CEO Doug Howe pointed to 'persistent instability and pressure on consumer discretionary' spending, and the company's stock tumbled 18.2%. The uncertainty is moving in both directions, to be sure. A survey released Tuesday of optimism among small U.S. businesses improved a bit in May. 'While the economy will continue to stumble along until the major sources of uncertainty are resolved, owners reported more positive expectations on business conditions and sales growth,' according to Bill Dunkelberg, chief economist at the National Federation of Independent Business. On Wall Street, J.M. Smucker fell 15.6% even though its results for the latest quarter topped analysts' expectations. Its revenue fell short of expectations, as did its forecast for profit in the upcoming year. Tesla helped to make up for such losses after rising 5.7%. The electric vehicle company has been recovering since tumbling last week as Elon Musk's relationship with Trump imploded. That raised fear about possible retaliation by the U.S. government against Tesla. Shares that trade in the United States of chipmaking giant Taiwan Semiconductor Manufacturing Co. rose 2.6% after the company known as TSMC said its revenue in May jumped nearly 40% from the year earlier. Casey's General Stores leaped 11.6% after the chain of convenience stores based in Ankeny, Iowa, reported a stronger profit for the latest quarter than analysts expected. It credited strength in sales of hot sandwiches and other items. All told, the S&P 500 rose 32.93 points to 6,038.81. The Dow Jones Industrial Average added 105.11 to 42,866.87, and the Nasdaq composite climbed 123.75 to 19,714.99. In stock markets abroad, indexes were mixed amid mostly modest movements across Europe and Asia. A 0.8% drop for Germany's DAX and a 0.6% gain for South Korea's Kospi were two of the bigger moves. In the bond market, the yield on the 10-year Treasury eased to 4.47% from 4.49% late Monday. Choe writes for the Associated Press.
Yahoo
an hour ago
- Yahoo
Senate Republican calls July 4 ‘false deadline' for megabill
Sen. John Curtis (R-Utah), a moderate Republican, called July 4 a 'false deadline' for Republicans to pass their megabill and said it's more important for the Senate to get it done 'right' than fast. In an interview at Politico's Energy Summit in Washington on Tuesday, Curtis said he's confident the bill would eventually pass. But, he added, 'I can't tell you what it's going to look like or when it's going to pass.' He signaled a lightly less optimistic note on whether it would pass by the GOP's self-imposed July 4 deadline. 'Well, let me just say, I think a lot of us would be surprised if it passed by July 4,' Curtis said. 'I think that's a false deadline,' he added. 'I don't think that we need to put a specific deadline on it. Let's get it right.' Other GOP senators have also publicly and privately voiced doubts about meeting the July 4 deadline that Senate Majority Leader John Thune (R-S.D.) is shooting for as Senate Republicans remain divided on a number of hot-button issues. On Monday, Speaker Mike Johnson (R-La.) said he thinks the deadline is still realistic. 'We certainly hope, I believe, we can still meet that,' Johnson said. 'It's up to the Senate, the bill's in the Senate's hands now. But I spoke with Leader Thune as recently as last night, he's feeling very optimistic.' At Tuesday's summit, Curtis said he thinks the House-passed version unfairly rolls back some of the energy tax credits in Biden-era Inflation Reduction Act (IRA). He said some of those tax credits 'have run their life cycle' but it's important to 'be thoughtful in how we phase them out.' 'Banks, investors have invested billions of dollars based on the rules of the road, and you have employees who have set careers based on these things,' Curtis said. 'Let's not destroy careers and things like that,' he added. 'Let's give people a chance to adjust. So in the case of those that it's time to phase them out, I think how we phase them out matters.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
